MX2022015114A - Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. - Google Patents

Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.

Info

Publication number
MX2022015114A
MX2022015114A MX2022015114A MX2022015114A MX2022015114A MX 2022015114 A MX2022015114 A MX 2022015114A MX 2022015114 A MX2022015114 A MX 2022015114A MX 2022015114 A MX2022015114 A MX 2022015114A MX 2022015114 A MX2022015114 A MX 2022015114A
Authority
MX
Mexico
Prior art keywords
neoantigen
complex
methods
antibodies targeting
classical hla
Prior art date
Application number
MX2022015114A
Other languages
English (en)
Inventor
Jon Weidanz
Katherine Upchurch-Ange
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022015114A publication Critical patent/MX2022015114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proporcionan anticuerpos que se unen selectivamente a un complejo que comprende un HLA-I no clásico (por ejemplo, HLA-E) y un neoantígeno que tiene dominios variables de la cadena pesada (VH), dominios variable de la cadena ligera (VL) y regiones determinantes de complementariedad (CDR) como se divulga en la presente, así como métodos y usos de los mismos.
MX2022015114A 2020-06-01 2021-06-01 Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. MX2022015114A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032747P 2020-06-01 2020-06-01
US17/199,205 US11359023B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
PCT/US2021/035290 WO2021247607A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (1)

Publication Number Publication Date
MX2022015114A true MX2022015114A (es) 2023-03-24

Family

ID=75495114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015114A MX2022015114A (es) 2020-06-01 2021-06-01 Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.

Country Status (19)

Country Link
US (4) US10981996B1 (es)
EP (1) EP4157882A4 (es)
JP (1) JP7650351B2 (es)
KR (1) KR20230019468A (es)
CN (1) CN116367865A (es)
AR (1) AR122501A1 (es)
AU (1) AU2021284275A1 (es)
BR (1) BR112022024275A2 (es)
CA (1) CA3174090A1 (es)
CL (1) CL2022003336A1 (es)
CO (1) CO2022018426A2 (es)
CR (1) CR20220652A (es)
DO (1) DOP2022000268A (es)
EC (1) ECSP22097197A (es)
IL (1) IL298020A (es)
MX (1) MX2022015114A (es)
PE (1) PE20230306A1 (es)
TW (1) TW202235439A (es)
WO (1) WO2021247607A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210253713A1 (en) * 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
EP4504345A1 (en) * 2022-04-08 2025-02-12 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP2386854A1 (en) * 2005-04-19 2011-11-16 Prediction Sciences LLC Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
ES2666550T3 (es) 2011-04-19 2018-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
HK1211299A1 (en) 2013-02-26 2016-05-20 罗切格利卡特公司 Bispecific t cell activating antigen binding molecules
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
SG10202006685XA (en) 2014-10-23 2020-08-28 Innate Pharma Treatment of Cancers Using Anti-NKG2A Agents
KR102663073B1 (ko) 2015-01-08 2024-05-07 젠맵 에이/에스 Cd3 및 cd20에 대항한 이중특이적 항체
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018140525A1 (en) 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer
EP3755371A4 (en) 2018-02-23 2021-11-24 Abexxa Biologics, Inc. ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN
US20210253713A1 (en) 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Also Published As

Publication number Publication date
AU2021284275A1 (en) 2023-01-19
TW202235439A (zh) 2022-09-16
DOP2022000268A (es) 2023-01-15
IL298020A (en) 2023-01-01
US12173072B2 (en) 2024-12-24
CR20220652A (es) 2023-07-03
EP4157882A4 (en) 2024-06-26
US20240026007A1 (en) 2024-01-25
US20220332831A1 (en) 2022-10-20
US10981996B1 (en) 2021-04-20
AR122501A1 (es) 2022-09-14
BR112022024275A2 (pt) 2023-05-02
CA3174090A1 (en) 2021-12-09
CL2022003336A1 (es) 2023-06-23
EP4157882A1 (en) 2023-04-05
CN116367865A (zh) 2023-06-30
CO2022018426A2 (es) 2022-12-30
US11359023B2 (en) 2022-06-14
PE20230306A1 (es) 2023-02-13
KR20230019468A (ko) 2023-02-08
US20210371532A1 (en) 2021-12-02
WO2021247607A1 (en) 2021-12-09
ECSP22097197A (es) 2023-02-28
JP2023530036A (ja) 2023-07-12
JP7650351B2 (ja) 2025-03-24

Similar Documents

Publication Publication Date Title
MX2022015129A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.
MX2022015114A (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.
ZA202101258B (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
PH12019502785A1 (en) Anti trbc1 antigen binding domains
NZ752294A (en) Cd3 binding antibodies
WO2019147863A3 (en) Mica/b antibodies and methods of use
NZ595235A (en) Compositions and methods for increasing muscle growth
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
IL299221A (en) Cd3 binding antibodies
NZ626269A (en) Anti-phf-tau antibodies and their uses
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
NZ600112A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
MX2009009782A (es) Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
AR122502A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
CY1121950T1 (el) Νεα αντισωματα εναντι φωσφορυλχολινης
MX2024002260A (es) Anticuerpo tetravalente bispecifico dirigido a egfr y her3.
FR3061716B1 (fr) Nouveaux composes ciblant le cd160 humain
WO2022026807A3 (en) Antibodies targeting sars-cov-2 and uses thereof
TH2101000588A (th) แอนติบอดีสารต้าน mica/b ที่ขัดขวางการปลดออกของ mica/b และวิธีของการใช้
WO2021154978A3 (en) Human blood-brain barrier targeting antibodies
WO2024243255A3 (en) Methods of treating cancer with anti-mica/b antibodies
AR122257A2 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
TH93924B (th) โมเลกุลแอนติบอดีซึ่งเชื่อมจับ il-17 ของมนุษย์